Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis

Archives of Dermatological Research

Volumn 295, Issue 11, 2004, Pages 465-473

  Goedkoop, Amber Y ^a   De Rie, Menno A ^a   Picavet, Daisy I ^a   Kraan, Maarten C ^a   Dinant, Huib J ^a,b   Van Kuijk, Arno W R ^a,b   Tak, Paul P ^a   Bos, Jan D ^a   Teunissen, Marcel B M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

Immunotherapy; Inflammation; Psoriasis; Skin; T lymphocytes

Indexed keywords

ALEFACEPT; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DERMIS; EFFECTOR CELL; EPIDERMIS CELL; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; OPEN STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; SINGLE BLIND PROCEDURE; SKIN BIOPSY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; E-SELECTIN; EPIDERMIS; HUMANS; IMMUNOLOGIC MEMORY; INTERCELLULAR ADHESION MOLECULE-1; PSORIASIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 2142711704     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-004-0450-y     Document Type: Article

References (38)

1. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG (1998) Intraepidermal lymphocytes in psoriatic: lesions are activated GMP-17 (TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 25:79-88
2. Baker BS, Swain AF, Fry L, Valdimarsson H (1984) Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110:555-564
3. Baker BS, Griffiths CEM, Lambert S, Powles AV, Leonard JN, Valdimarsson H, Fry L (1987) The effects of cyclosporin A on T lymphocytes and dendritic cell sub-populations in psoriasis. Br J Dermatol 116:503-510
4. Bjerke JR (1982) In situ characterization and counting of monomiclear cells in lesions of different clinical forms of psoriasis. Acta Derm Venereol 62:93-100
5. Bjerke JR, Krogh H-K, Matre R (1978) Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol 71:340-343
6. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH (1983) Immunocompetent cells in psoriasis. In situ phenotyping by monoclonal antibodies. Arch Dermatol Res 275:181-189
7. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML (1989) Predominance of "memory" T cells (CD4+, CDw29+) over"naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 281:24-30
8. Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, Alexander DR (2003) Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 33:666-675
9. Danielian S, Fagard R, Alcover A, Acuto O, Fischer S (1991) The tyrosine kinase activity of p561ck is increased in human T cells activated via CD2. Eur J Immunol 21:1967-1970
10. Da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu Y-M, Hochman PS (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signalling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol 168:4462-4471
11. Dustin ML, Springer TA (1991) Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 9:27-66
12. Dustin ML, Sanders ME, Shaw S, Springer TA (1987) Purified lymphocyte function-associated antigen-3 (LFA-3) binds to CD2 and mediates T lymphocyte adhesion. J Exp Med 165: 677-692
13. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New Engl J Med 345:248-255
14. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM (2000) CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 14:63-78
15. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM (1986) Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 164:1013-1028
16. Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, Granelli-Pipemo A, Rivas M, Barazani L, Krueger JG (1992) Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 98:302-309
17. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M (2002) Psoriasis as a model for T-cell mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of Efalizumab, an anti-CD11a antibody. Arch Dermatol 138:591-600
18. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1: 442-447
19. Griffiths CEM, Voorhees JJ, Nickoloff BJ (1989) Characterization of ICAM-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant IFN-gamma and TNF-alpha. J Am Acad Dermatol 20:617-629
20. Hammar H, Gu S-Q, Johannesson A, Sundkvist K-G, Biberfeld P (1984) Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during evolution of the lesion. J Invest Dermatol 83:416-420
21. Henseler T, Christophers E (1985) Psoriasis of early and late-onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450-456
22. June CH, Fletcher MC, Ledbetter JA, Samelson LE (1990) Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol 144:1591-1599
23. Kobayashi S, Sugiyama H, Gyulai R, McCormick T, Korman N, Stevens S, Cooper K, Vaishnaw A, Shrager D (2001) Alefacept treatment for psoriasis reduces the number of infiltrating IFN-γ+-producing T cells in lesional skin (abstract). J Invest Dermatol 117:546
24. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP (2000) Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 39: 43-49
25. Kraan MC, van Kuijk AWR, Dinant HJ, Goedkoop, Smeets TJM, de Rie MA, Dijkmans BAC, Vaishnaw AK, Bos JD, Tak PP (2002) Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46:2776-2784
26. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, Austin LM, Gottlieb AB (1995) Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cell. J Exp Med 182:2057-2068
27. Krueger JG, Gilleaudeau P, Kikuchi T, Lee E (2002) Alefacept selectively reduces subpopulations of memory CD4+ and CD8+ T cells (abstract). J Invest Dermatol 119:759
28. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS (1994) Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 152:2753-2767
29. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner B (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178:211-222
30. + perivascular cells. J Invest Dermatol 96:333-340
31. Reich K, Mossner R, Koning IR, Westphal G, Ziegler A, Neumann C (2002) Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 118:155-163
32. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S (1988) Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and have three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 140:1401-1407
33. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Buschenfelde KH, Fleischer B (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149
34. Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987) The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 5:223-252
35. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705
36. Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, Hodak E, Gottlieb AB, Krueger JG (1994) PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 180:283-296
37. Wallace DL, Beverley PC (1990) Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells. Immunology 69:460-467
38. Wawryk SO, Novotny JR, Wicks IP, Wilkinson D, Maher D, Salvaris E, Welch K, Fecondo J, Boyd AW (1989) The role of the LFA-ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 108:135-161